Cancer vaccines for established cancer: how to make them better?
/in International Publications, Malignant MelanomaStrategies and challenges in eliciting immunity to melanoma
/in International Publications, Malignant MelanomaAn effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusThe efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells
/in HIV/AIDS, International PublicationsReengineering dendritic cell-based anti-cancer vaccines
/in Breast Cancer, International PublicationsTherapeutic efficacy of antitumor dendritic cell vaccinations correlates with persistent Th1 responses, high intratumor CD8+ T cell recruitment and low relative regulatory T cell infiltration
/in Glioblastoma, International PublicationsVaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response
/in Chronic Leukemia, International PublicationsHyperthermia improves the antitumour effect of metronomic cyclophosphamide in a rat transplantable brain tumour
/in Glioblastoma, International PublicationsBrain tumor therapy by combined vaccination and antisense oligonucleotide delivery with nanoparticles
/in International Publications, Newcastle Disease Virus
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer